Results 111 to 120 of about 7,028 (198)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

Treatment Outcomes of Hospitalized Patients With Inflammatory Bowel Disease at a Tertiary Care Center in Nepal: A Cross‐Sectional Study

JCC Plus, Volume 1, Issue 4, July 2026.
Overall, patients with IBD constituted 1.6% (n = 37) of all admissions to the gastroenterology ward for any indication. Most (2/3rd) hospitalized patients with IBD responded to conventional therapy; one third required advanced therapy or surgery. In‐hospital mortality was high at 5%, probably related to delayed diagnosis, limited access to advanced ...
Ajay Kumar Yadav, Bhupendra Kumar Basnet, Ramila Shrestha, Ajit Khanal, Milan Shrestha, Mukesh Sharma Poudel   +5 more
wiley   +1 more source

Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis [PDF]

Background & Aims: Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC).
?, ?
core   +1 more source

Sustained Treatment Success With Ustekinumab in Symptomatic Stricturing Crohn's Disease: A Retrospective Single‐Arm Observational Cohort Study

MedComm, Volume 7, Issue 7, July 2026.
Data on ustekinumab (UST) for symptomatic stricturing Crohn's disease remain scarce in China. This cohort study screened 73 patients from June 2022 to April 2024, of whom 54 were eligible included, with 81.5% achieving 52‐week treatment success. Most attained sustained clinical remission alongside improved inflammation and strictures. Nonsmoking status
Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen   +5 more
wiley   +1 more source

Real‐World Maintenance of Remission in Atopic Dermatitis Patients With Upadacitinib: A Multicenter Retrospective Study in Japan (ROADMAP Study)

The Journal of Dermatology, Volume 53, Issue 7, Page 980-989, July 2026.
ABSTRACT Upadacitinib (UPA) is a selective Janus kinase 1 inhibitor that improves moderate‐to‐severe atopic dermatitis, but real‐world strategies to maintain remission after response remain unclear. We conducted a multicenter retrospective study in Japan of 219 patients aged ≥ 12 years who achieved protocol‐defined remission, defined as Investigator's ...
Yuichiro Tsunemi, Atsuyuki Igarashi, Takeshi Ishido, Hidehisa Saeki   +3 more
wiley   +1 more source

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Journal of Dermatological Treatment
Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported ...
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley   +12 more
doaj   +1 more source

2024 Update of the Asia‐Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier ...
Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, Yuko Kaneko, Wanruchada Katchamart, Manjari Lahiri, Chin Teck Ng, Babur Salim, Keshav Raj Sigdel, Shereen Ch'ng Suyin, Tsutomu Takeuchi, Galymzhan Togizbayev, Evan Vista, Sandini Wijeweera, Chuanhui Xu, Chak Sing Lau   +22 more
wiley   +1 more source

Successful treatment of prurigo nodularis with upadacitinib [PDF]

Prurigo nodularis (PN) is a debilitating condition marked by raised, intensely itchy, often painful nodules on the skin. A 50-year-old man presented with a 7-year history of PN lesions on his trunk and extremities.
Barei, Francesca, Bombelli, Andrea, Termini, Davide, Avallone, Gianluca, Ferrucci, Silvia M, Marzano, Angelo V, Chiei-Gallo, Alessandra   +6 more
core   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 2, Page 235-242, July 2026.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source